

Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis

Sherry Rodriguez

Department of Oral Biology and Pathology, School of Dental
Medicine, Stony Brook University, Stony Brook, New York, United
States of America

01-01-2013

1 Abstract

(CNN) Targeting breast cancer-initiating cells with the perc-Merck therapy Lymphocyte Antigen Receptor (LAR)-7-inhibiting potentiation-9, and scaling the effect to improve outcomes for patients has a large clinical development plan, an expert panel on metastatic melanoma at the American Society of Clinical Oncology panel last week found.

This is a potential treatment approach that would work in patients who have been hesitant to [expand] their treatment regimens by injecting more regimens, said Dr. Antonio Garcia-Martinez, chief medical officer at Eli Lilly & Co. in New Brunswick, New Jersey.

The drug magnate last year acquired nearly 70% of Mercks share of the Array Array Biosciences cancer immunotherapy research platform, which operates independently of the companys drug pipeline.

The talcitabine drug helps patients with mild to moderate stage 4 non-small cell lung cancer react to a series of checkpoint inhibitors that typically block a patients reward system when theyre irradiated or knocked down with chemotherapy.

A report published last month in the New England Journal of Medicine shows that so-called late-stage melanoma patients who currently receive at least three treatment regimens (placebo-co- therapy, chemotherapy and radiation) every four months for about five years had a greater increased risk of an at-home diagnosis of melanoma in May 2012, indicating more trials are needed to assess whether initial therapy is worthwhile or valuable.

1.1 Image Analysis




Figure 1: A Close Up Of A Person With A Dog